Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).

Trial Details

NCT ID
NCT07078591
Phase
PHASE2
Sponsor
Beijing 302 Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Azacitidine (AZA)
  • Daunorubicin
  • Idarubicin（IDA）
  • Cytarabine (Ara-C)
  • GPBMC infusion
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age \>=18 years, male or female, non-limited by race or ethnicity.
  • No prior anti-acute leukemia treatment (including hypomethylators for leukemia or MDS) with the exception that prior hydroxyurea and/or leukapheres…
  • Confirmed acute myeloid leukemia in accordance with WHO criteria with a WBC count \< 25 × 109/L.
  • Adequate hepatic function including alanine transaminase (ALT) and aspartate aminotransferase (AST )\<= 3 × upper limit of normal(ULN), and total b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →